Home / Investors / Press releases

Press releases

Here you will find all press releases from XVIVO.

Showing 1 to 30 out of 328 posts.

10 Oct, 2024

Conference call on Interim Report

19 Sep, 2024

XVIVO to acquire a unique communication platform for the transplant process

6 Sep, 2024

Nomination Committee of XVIVO Perfusion AB (publ)

16 Aug, 2024

Results from European randomized controlled study using XVIVO’s heart technology published in The Lancet

12 Jul, 2024

Interim report January – June 2024

25 Jun, 2024

Conference call on Interim Report

25 Apr, 2024

Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

24 Apr, 2024

Interim report January-March 2024

11 Apr, 2024

Results from XVIVO’s clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague

8 Apr, 2024

Conference call on Interim Report

4 Apr, 2024

Annual Report 2023

21 Mar, 2024

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)

29 Feb, 2024

The first-ever transplantation with a donor heart transported across the Atlantic Ocean – made possible by the use of XVIVO’s heart technology

25 Jan, 2024

XVIVO presents Report on Operations 2023

24 Jan, 2024

Extended perfusion time of livers can streamline planning and logistics – enabling more liver transplants to be performed during daytime

12 Jan, 2024

Conference call on Report on Operations 2023

22 Dec, 2023

XVIVO reaches milestone in Italy: 1,200 lifesaving perfusions performed with Liver Assist

14 Dec, 2023

XVIVO announces a write-down related to PrimECC of SEK 17 million not affecting cashflow or EBITDA

3 Nov, 2023

Results from a Australian/New Zealand study using XVIVO’s heart technology published

24 Oct, 2023

Interim report January-September 2023

23 Oct, 2023

Leading acacemic medical center performs first heart transplant in the U.S. utilizing NIHP technology as part of XVIVO’s PRESERVE clinical trial

6 Oct, 2023

Conference call on Interim Report

29 Sep, 2023

Increased number of shares and votes in XVIVO Perfusion AB (publ)

29 Sep, 2023

Nomination committee of XVIVO Perfusion AB (publ)

13 Sep, 2023

XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million

13 Sep, 2023

XVIVO intends to carry out a directed share issue

25 Jul, 2023

US FDA grants XVIVO approval to include DCD hearts in IDE Clinical Trial

13 Jul, 2023

XVIVO presents interim report January-June 2023

12 Jul, 2023

XVIVO has decided to close the PrimECC® study for further patient inclusions – strategic opportunities will be evaluated

10 Jul, 2023

XVIVO enters into a strategic collaboration with MTJ Aviation to strengthen organ procurement services in the US